Shares of Crispr Theraptc (NASDAQ:CRSP) have received an average rating of “Buy” from the eight analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $23.00.

CRSP has been the subject of a number of research reports. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price target for the company. Cann initiated coverage on shares of Crispr Theraptc in a report on Monday, July 17th. They issued a “market perform” rating for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Chardan Capital reissued a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. Finally, Barclays PLC reissued a “buy” rating and issued a $29.00 price target on shares of Crispr Theraptc in a report on Friday, September 8th.

COPYRIGHT VIOLATION WARNING: “Crispr Theraptc (CRSP) Receives Consensus Recommendation of “Buy” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/26/crispr-theraptc-crsp-receives-consensus-recommendation-of-buy-from-analysts.html.

Crispr Theraptc (NASDAQ CRSP) opened at 18.95 on Tuesday. The firm has a 50-day moving average price of $19.03 and a 200-day moving average price of $19.03. Crispr Theraptc has a one year low of $13.75 and a one year high of $25.00. The firm’s market capitalization is $769.20 million.

Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.06. The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. The company’s quarterly revenue was up 350.0% on a year-over-year basis. Equities analysts anticipate that Crispr Theraptc will post ($2.43) earnings per share for the current year.

In other news, Director Kurt Von Emster sold 43,202 shares of Crispr Theraptc stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $16.90, for a total transaction of $730,113.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Rodger Novak sold 75,795 shares of Crispr Theraptc stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $20.25, for a total transaction of $1,534,848.75. Following the transaction, the chief executive officer now directly owns 1,232,697 shares in the company, valued at $24,962,114.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 673,071 shares of company stock worth $12,526,999. Insiders own 39.98% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. IHT Wealth Management LLC bought a new position in shares of Crispr Theraptc during the first quarter worth $110,000. Monashee Investment Management LLC lifted its position in Crispr Theraptc by 208.7% in the 1st quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after acquiring an additional 15,000 shares in the last quarter. Paulson & CO. Inc. bought a new stake in Crispr Theraptc in the 1st quarter valued at $1,099,000. Credit Suisse AG bought a new stake in Crispr Theraptc in the 1st quarter valued at $1,742,000. Finally, Wellington Management Group LLP lifted its position in Crispr Theraptc by 0.4% in the 1st quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after acquiring an additional 3,070 shares in the last quarter. 23.90% of the stock is currently owned by institutional investors.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Analyst Recommendations for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.